The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, first blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.